This SuperSeries is composed of the SubSeries listed below.
Overall design: Refer to individual Series
| Accession | PRJNA470767; GEO: GSE114275 |
| Type | Umbrella project |
| Publications | Gui B et al., "Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.", Proc Natl Acad Sci U S A, 2019 Jul 16;116(29):14573-14582 |
| Submission | Registration date: 10-May-2018
Thorn 1529, Surgery, Brigham and Women's Hospital |
| Relevance | Superseries |
Project Data:
| Resource Name | Number
of Links |
|---|
| Sequence data |
| SRA Experiments | 31 |
| Publications |
| PubMed | 1 |
| PMC | 1 |
| Other datasets |
| BioSample | 31 |
| GEO DataSets | 3 |
Selective Targeting of PARP2 Inhibits Androgen Receptor Signaling and Prostate Cancer Growth Through Disruption of FOXA1 Function encompasses the following 2 sub-projects:
| Project Type | Number of Projects |
| Epigenomics | 1 |
BioProject
accession | Organism | Title |
|---|
| PRJNA471000 | Homo sapiens | Genome-wide occupation of AR, FOXA1, and H3K27AC in LNCaP cells treated with selective PARP2 inhibitor UPF-1069 (Thorn 1529, Surgery, Brigham...) |
|
| Transcriptome or Gene expression | 1 |
BioProject
accession | Organism | Title |
|---|
| PRJNA471001 | Homo sapiens | Gene expression profilings for prostate cancer cells after inhibition of PARP1 or PARP2 using pharmaceutical or siRNA-based approaches (Thorn 1529, Surgery, Brigham...) |
|